Heartflow Inc. completes $364.2 million IPO, trading on Nasdaq under ticker HTFL, enhancing coronary artery disease care with AI technology.
Quiver AI Summary
Heartflow, Inc., a leader in AI technology for coronary artery disease, announced the successful closure of its upsized initial public offering, selling 19,166,667 shares at $19 each, which raised approximately $364.2 million before expenses. The company's shares began trading on the Nasdaq Global Select Market under the ticker symbol “HTFL” on August 8, 2025. The offering was managed by J.P. Morgan, Morgan Stanley, and Piper Sandler, with Stifel and Canaccord Genuity serving as co-managers. Heartflow’s technology, particularly its Heartflow One platform, aims to improve coronary care by making coronary artery disease more manageable and is supported by extensive clinical research.
Potential Positives
- Heartflow successfully closed an upsized initial public offering, raising approximately $364.2 million, which enhances its financial position for future growth and innovation.
- The company's common stock began trading on the Nasdaq Global Select Market, increasing visibility and credibility in the investment community.
- Heartflow is recognized as a leader in AI technology for coronary artery disease, positioning itself at the forefront of advancements in healthcare technology.
Potential Negatives
- Heartflow's upsized initial public offering may indicate a reliance on external capital to fuel growth, which could signal potential financial instability or a lack of sufficient internal funding.
- The fact that all shares were offered by Heartflow could suggest a significant dilution of existing shares, impacting current shareholders' equity negatively.
- The need for the company to raise substantial funds through an IPO may raise concerns among investors about its profitability and long-term sustainability.
FAQ
What is Heartflow's recent IPO news?
Heartflow, Inc. announced the closing of its upsized IPO, raising approximately $364.2 million by offering 19,166,667 shares at $19 each.
What ticker symbol is Heartflow listed under?
Heartflow's common stock began trading on the Nasdaq under the ticker symbol "HTFL" on August 8, 2025.
Who managed Heartflow's IPO offering?
J.P. Morgan, Morgan Stanley, and Piper Sandler were the joint book-running managers for Heartflow's IPO, with Stifel and Canaccord Genuity as co-managers.
How can I obtain the prospectus for Heartflow's offering?
The prospectus for Heartflow's offering can be obtained from J.P. Morgan, Morgan Stanley, or Piper Sandler via specified contact details in the press release.
What services does Heartflow provide in coronary care?
Heartflow offers a non-invasive, precision coronary care platform assisting in managing coronary artery disease through advanced AI technology and analyses.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
MOUNTAIN VIEW, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), a leader in AI technology for coronary artery disease (CAD), today announced the closing of its upsized initial public offering of 19,166,667 shares of its common stock at a public offering price of $19 per share, which includes 2,500,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. All of the shares of common stock were offered by Heartflow. The total gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Heartflow, were approximately $364.2 million. Heartflow’s common stock began trading on the Nasdaq Global Select Market on August 8, 2025 under the ticker symbol “HTFL.”
J.P. Morgan, Morgan Stanley and Piper Sandler acted as joint book-running managers for the offering. Stifel and Canaccord Genuity acted as co-managers for the offering.
A registration statement relating to the shares sold in this offering was filed with, and declared effective by, the U.S. Securities and Exchange Commission. The offering was made only by means of a prospectus, copies of which may be obtained from J.P. Morgan, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected] and [email protected] ; Morgan Stanley, 180 Varick Street, 2nd Floor, New York, NY 10014, Attention: Prospectus Department, or by email at [email protected] ; or Piper Sandler & Co., Attention: Prospectus Department, 350 North 5th Street, Suite 1300, Minneapolis, MN 55402, by telephone at (800) 747-3924 or by email at [email protected] .
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Heartflow, Inc.
Heartflow is advancing coronary care by transforming coronary artery disease into a screenable, diagnosable, and manageable condition. Heartflow One is the only complete, non-invasive, precision coronary care platform providing patient insights throughout the guideline-directed CCTA pathway. The AI-driven platform — including Roadmap™ Analysis, FFR
CT
Analysis and Plaque Analysis — is supported by the ACC/AHA Chest Pain Guideline and backed by more than 600 peer-reviewed publications. Heartflow has helped clinicians manage over 400,000 patients worldwide.
Media Contact
Elliot Levy
[email protected]
Investor Contact
Nick Laudico
[email protected]
